[ad_1]
According to a guide provided to British health workers, the effectiveness of a safe dose of the AstraZeneca vaccine is 52.7%, but a health official said the effectiveness should be 70% after the first dose.
Vaccine efficacy
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) recommends giving the second dose within four to 12 weeks of the first, emphasizing that a 80% efficiency it was obtained within a three-month interval between the two doses.
Clinical trials of this vaccine have caused confusion after preliminary results announced in late November revealed different effects at different doses. Thus, after accidental administration of only half the dose to a group of volunteers, in their case an efficacy of 90% was observed, compared to only 62% in the case of those who received the scheme with two full doses. AstraZeneca continues testing, but the MHRA says its evaluation that licensed the vaccine did not take into account the results of a single half dose.
The decision of the UK authorities to rapidly authorize this vaccine aims to inoculate as many people as possible in a short time, even before the answer to all questions about efficacy and optimal dose is clear. In the absence of concerns about vaccine safety, the British regulator has tried to strike a compromise between hoping for perfection and making the decisions necessary to combat the pandemic.
Desi the efficacy of the AstraZeneca vaccine It is smaller than the Pfizer-BioNTech vaccine, given the insufficient number of doses available, this vaccine may play an important role in the fight against the pandemic.
The cost of vaccines
In addition, the AstraZeneca vaccine will cost only a few dollars a dose, while the price of a dose of the Pfizer-BioNTech vaccine reaches $ 18.40-19.50, and that of the Modern vaccine (approved in the US) up to $ 37 the dose.
Additionally, the AstraZeneca vaccine does not require transportation and storage at temperatures of -70 degrees Celsius, as is the case with the Pfizer-BioNTech vaccine, and can be stored in a normal refrigerator for six months.
The principle of the AstraZeneca vaccine is a “viral vector”, that is, a specially adapted virus that causes the common cold in chimpanzees and transmits genetic instructions to human cells to separate the Spike protein from the surface of the SARS-CoV- virus. 2.
The Pfizer-BioNTech vaccine uses a new messenger RNA technology, which transmits genetic information to human cells to produce the Spike protein, which will trigger the antibody-producing immune response.
As was the case with the Pfizer-BioNTech vaccine, which obtained its first UK authorization in early December, regulators in other countries could also come under pressure to make a decision.
The European Medicines Agency (EMA) has provisionally authorized the Pfizer-BioNTech vaccine and will decide on January 6 on the Modern, but, regarding the AstraZeneca vaccine, it warned that it has not yet received the authorization request and the complete documentation, its analysis being carried out so far solely on the basis of the data received during the “continuous evaluation” process that began on 1 December. . Therefore, the issuance of a conditional marketing authorization (CMA) in the EU by the end of January is unlikely, estimates the EMA. However, a German medical official said he expected a “quick decision” from the European agency, as the analysis of the ongoing evaluation is well under way.
On the other hand, once more vaccines become available, governments will have to decide the criteria for their distribution, as people usually want the vaccine to be given as effectively as possible, but this is not the case. immediately after, as there are insufficient amounts of vaccine
Read also:
What does the COVID-19 vaccine contain and how specialists explain the technology used by manufacturing companies
Main countries with population vaccinated against COVID. Where is Romania?
[ad_2]
